Specialised Therapeutics Acquires Commercialisation Rights To New Oral Mnd Therapy

By Author: Ben Gross
Total Articles: 460
Comment this article

Specialised Therapeutics Asia (ST), an independent biopharmaceutical company, is collaborating with Treeway BV, a Dutch biotechnology firm, to bring a new therapy called TW001 for treating Amyotrophic Lateral Sclerosis (ALS) to Australia and New Zealand. ALS is the most common form of Motor Neurone Disease (MND). TW001 is an oral formulation of edaravone, designed to reduce oxidative damage linked to neuron death in ALS. The treatment is currently in a pivotal phase III registration study called ADORE, conducted at almost 40 global sites.

Around 2000 people in Australia live with MND at any given time, and an oral therapy like edaravone could allow home-based management. Specialised Therapeutics will handle all marketing, regulatory, and distribution activities of TW001 for ALS/MND in Australia and New Zealand under the licensing agreement. This partnership marks ST's commitment to offering unique therapies in the region, focusing on making treatments accessible that might otherwise not be available.

Treeway CEO Inez de Greef noted the promising results of TW001 and the company's anticipation of working with ST ...
... to make the therapy available to eligible patients in the region. ST Chief Executive Officer Carlo Montagner expressed optimism about TW001's potential to slow disease progression and improve outcomes for ALS patients.

More Information : https://www.techdogs.com/tech-news/pr-newswire/specialised-therapeutics-acquires-commercialisation-rights-to-new-oral-mnd-therapy